ECSP13012467A - Uso de aglutinantes para fabricar formulaciones estables al almacenamiento - Google Patents

Uso de aglutinantes para fabricar formulaciones estables al almacenamiento

Info

Publication number
ECSP13012467A
ECSP13012467A ECSP13012467A ECSP13012467A EC SP13012467 A ECSP13012467 A EC SP13012467A EC SP13012467 A ECSP13012467 A EC SP13012467A EC SP13012467 A ECSP13012467 A EC SP13012467A
Authority
EC
Ecuador
Prior art keywords
storage
manufacture
binders
formulations
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Derek Allan Prater
Christof Spitzley
Gerhard Josef Heun
Alexander Schütz
Udo Hahn
Christian Leuner
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012467(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of ECSP13012467A publication Critical patent/ECSP13012467A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas de dosificación farmacéuticas, de liberación prolongada, estables al almacenamiento, que comprenden oxicodona o una sal farmacéuticamente aceptable de la misma y naloxona o una sal farmacéuticamente aceptable de la misma, a la fabricación de las mismas así como a su uso para la administración a seres humanos.
ECSP13012467 2010-08-13 2013-02-28 Uso de aglutinantes para fabricar formulaciones estables al almacenamiento ECSP13012467A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37334410P 2010-08-13 2010-08-13
EP10172759 2010-08-13

Publications (1)

Publication Number Publication Date
ECSP13012467A true ECSP13012467A (es) 2013-03-28

Family

ID=43382375

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012467 ECSP13012467A (es) 2010-08-13 2013-02-28 Uso de aglutinantes para fabricar formulaciones estables al almacenamiento

Country Status (29)

Country Link
US (2) US20130245054A1 (es)
EP (2) EP2603205B1 (es)
JP (1) JP6007176B2 (es)
KR (1) KR101518143B1 (es)
CN (1) CN103118668B (es)
AR (1) AR082688A1 (es)
AU (1) AU2011288413B2 (es)
BR (1) BR112013003150B1 (es)
CA (1) CA2805974C (es)
CH (1) CH705678B1 (es)
CL (1) CL2013000444A1 (es)
CO (1) CO6680640A2 (es)
DE (1) DE112011102708T5 (es)
DK (1) DK178702B1 (es)
EC (1) ECSP13012467A (es)
ES (1) ES2409069B2 (es)
GB (1) GB2495676B (es)
MX (1) MX355644B (es)
MY (1) MY165149A (es)
NO (1) NO20130366A1 (es)
NZ (1) NZ606123A (es)
PE (1) PE20131101A1 (es)
PH (1) PH12013500172A1 (es)
RU (1) RU2572695C2 (es)
SE (1) SE537698C2 (es)
SG (1) SG187678A1 (es)
SI (1) SI2603205T1 (es)
TW (1) TWI469781B (es)
WO (1) WO2012020097A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
CA2478515C (en) 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
NZ603173A (en) 2010-05-10 2014-10-31 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
US20180104236A1 (en) 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
DK3609464T3 (da) * 2017-04-13 2021-08-30 Jean Paul Remon Xanthohumolbaserede sammensætninger
CN111686094A (zh) * 2020-07-13 2020-09-22 云南民族大学 一种脂肪醇类化合物在制备通便药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164669B1 (de) 1984-06-13 1991-01-23 Röhm Gmbh Verfahren zum Überziehen von Arzneiformen
HU218673B (hu) * 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
JP4848558B2 (ja) * 2001-05-08 2011-12-28 トーアエイヨー株式会社 塩酸メトホルミン含有速放性錠剤
US7943173B2 (en) * 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
JP2003160487A (ja) * 2001-11-20 2003-06-03 Ohara Yakuhin Kogyo Kk プラバスタチンナトリウム含有錠剤およびその製造法
CA2478515C (en) * 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
DE102005048293A1 (de) * 2005-10-08 2007-04-12 Sanofi-Aventis Deutschland Gmbh Retardformulierung für Pralnacasan
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
JP2009298707A (ja) * 2008-06-11 2009-12-24 Ohara Yakuhin Kogyo Kk 粒子加工方法
DK3045043T3 (da) * 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse

Also Published As

Publication number Publication date
EP2603205B1 (en) 2018-10-03
SE1350286A1 (sv) 2013-03-21
ES2409069B2 (es) 2014-07-17
MX355644B (es) 2018-04-26
CH705678B1 (de) 2016-03-15
BR112013003150B1 (pt) 2022-01-18
KR20130083903A (ko) 2013-07-23
GB2495676B (en) 2018-08-22
MX2013001757A (es) 2013-05-06
ES2409069R1 (es) 2013-08-30
PH12013500172A1 (en) 2022-10-24
TW201228662A (en) 2012-07-16
SG187678A1 (en) 2013-03-28
RU2572695C2 (ru) 2016-01-20
AU2011288413A1 (en) 2013-02-21
CN103118668A (zh) 2013-05-22
US20160095853A1 (en) 2016-04-07
KR101518143B1 (ko) 2015-05-06
JP6007176B2 (ja) 2016-10-12
JP2013533303A (ja) 2013-08-22
DE112011102708T5 (de) 2013-05-29
PE20131101A1 (es) 2013-09-23
CA2805974C (en) 2019-11-26
RU2013110820A (ru) 2014-09-20
CN103118668B (zh) 2016-07-06
SI2603205T1 (sl) 2019-02-28
CA2805974A1 (en) 2012-02-16
EP3505162A1 (en) 2019-07-03
WO2012020097A2 (en) 2012-02-16
AR082688A1 (es) 2012-12-26
DK201370075A (en) 2013-02-13
AU2011288413B2 (en) 2014-05-22
GB201301916D0 (en) 2013-03-20
DK178702B1 (en) 2016-11-21
ES2409069A2 (es) 2013-06-24
SE537698C2 (sv) 2015-09-29
CO6680640A2 (es) 2013-05-31
WO2012020097A3 (en) 2012-05-03
GB2495676A (en) 2013-04-17
BR112013003150A2 (pt) 2020-09-08
CL2013000444A1 (es) 2013-08-23
US20130245054A1 (en) 2013-09-19
MY165149A (en) 2018-02-28
TWI469781B (zh) 2015-01-21
EP2603205A2 (en) 2013-06-19
NO20130366A1 (no) 2013-04-29
NZ606123A (en) 2015-03-27

Similar Documents

Publication Publication Date Title
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CY1118032T1 (el) Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
ES2446643R1 (es) Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
ECSP10010588A (es) Formulacion de medicamento solida con liberacion retardada
PH12012502082A1 (en) Combination of active loaded granules with additional actives
HK1208222A1 (en) Modified release formulations for oprozomib
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
BR112013007904A2 (pt) "composto, composição farmacêutica, medicamento, uso de um composto e proceso para preparar um composto"
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
CR11781A (es) Formulacion de medicamento solida con liberacion retardada
RU2011145777A (ru) Лекарственное средство, обладающее ранозаживляющей, противовоспалительной активностью